Funakushi Ryo, Kuba Sayaka, Morita Michi, Akashi Momoko, Eguchi Susumu
School of Medical Sciences, Nagasaki University, Nagasaki, JPN.
Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JPN.
Cureus. 2024 Sep 20;16(9):e69771. doi: 10.7759/cureus.69771. eCollection 2024 Sep.
A 37-year-old woman was diagnosed with stage IIIA, estrogen receptor (ER)-positive/human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The patient received neoadjuvant chemotherapy with epirubicin and cyclophosphamide, followed by docetaxel, trastuzumab, and pertuzumab. The surgical specimen remained ER-positive/HER2-positive. Liver metastasis was detected after the completion of postoperative adjuvant trastuzumab and pertuzumab. A liver biopsy following treatment with trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-Dxd) revealed HER2-negative status. Cyclin-dependent kinase (CDK) 4/6 inhibitor combination endocrine therapy has been continued for 16 months to date while maintaining tumor shrinkage. It is essential to perform a rebiopsy during treatment to optimize therapy based on the subtype.
一名37岁女性被诊断为IIIA期雌激素受体（ER）阳性/人表皮生长因子受体2（HER2）阳性乳腺癌。患者接受了表柔比星和环磷酰胺新辅助化疗，随后使用多西他赛、曲妥珠单抗和帕妥珠单抗。手术标本仍为ER阳性/HER2阳性。术后辅助使用曲妥珠单抗和帕妥珠单抗结束后检测到肝转移。在用曲妥珠单抗偶联物（T-DM1）和曲妥珠单抗德鲁替康（T-Dxd）治疗后进行的肝活检显示HER2阴性状态。细胞周期蛋白依赖性激酶（CDK）4/6抑制剂联合内分泌治疗迄今已持续16个月，同时肿瘤持续缩小。在治疗期间进行再次活检以根据亚型优化治疗至关重要。
